TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement